ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Oxytocin in Telling and Detecting Lies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02361177
Recruitment Status : Withdrawn (Drug not available)
First Posted : February 11, 2015
Last Update Posted : June 13, 2016
Sponsor:
Collaborator:
Harvard University
Information provided by (Responsible Party):
University of Texas at Austin

Brief Summary:
The investigators are interested in the impact of intranasal oxytocin in unethical behavior.

Condition or disease Intervention/treatment Phase
Dyssocial Behavior Drug: Oxytocin Early Phase 1

Detailed Description:
The objective of this project is to further explore the role of oxytocin in moral judgment and ethical behavior. Oxytocin is a peptide hormone produced in a variety of hypothalamic neurons. It is released into the brain or brought into general circulation through sensory stimuli in a pulsatile fashion. In social psychology research, oxytocin is hypothesized to coordinate both the causes and effects of positive social interactions in a biofeedback loop.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Role of Oxytocin in Telling and Detecting Lies
Study Start Date : January 2016
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Oxytocin

Arm Intervention/treatment
Experimental: oxytocin
Intranasal 24 IU oxytocin self-administration.
Drug: Oxytocin
Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
Other Name: syntocinon

Placebo Comparator: placebo
Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
Drug: Oxytocin
Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
Other Name: syntocinon




Primary Outcome Measures :
  1. Unethical behavior [ Time Frame: 130 minutes ]
    To measure unethical behavior, we will calculate whether participants took more money than they actually earned on a problem-solving task.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male

Exclusion Criteria:

  • _____ _____BP > 130/85, HRT > 95 (can be included at discretion of study physician/designee)

    • _____History of seizures
    • _____Neurological Disorder
    • _____Current psychiatric disorder
    • _____Previous psychiatric disorder (can be included at discretion of PI)
    • Date last episode (if > 1 year, include; if <1 year, at discretion of PI)
    • _____Current use of psychoactive drugs
    • _____Previous use of psychoactive drugs (can be included at discretion of PI) _____Date last medicated_____ _____Type of medication___________________________________
    • _____Current use of anticoagulants
    • _____Current use of corticosteroids
    • _____Previous head trauma (can be included at discretion of PI)
    • _____Alcoholism or substance abuse
    • _____Carcinoma of the breast or prostate
    • _____Renal or Hepatic diseases
    • _____Chronic lung diseases
    • _____Cancer
    • _____Liver problems
    • _____Hypertension/Cardiac diseases
    • _____Cardiovascular Disease
    • _____Nephritis
    • _____Diabetes (use of insulin) /Obesity
    • _____Endocrine disease or malignancy
    • _____Asthma (can be included as discretion of study physician/designee, if episodes are infrequent, nonmedicated, and no active problems at time of study)
    • Medication
    • Frequency of episodes____ _____Date of last episode_____
    • _____Migraines(can be included as discretion of study physician/designee, if episodes are infrequent, nonmedicated, and no active problems at time of study)
    • Medication _____Frequency of migraines_____ _____Date of last migraine_____
    • _____High levels of physical contact with women or children

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02361177


Sponsors and Collaborators
University of Texas at Austin
Harvard University
Investigators
Principal Investigator: Robert A Josephs, PhD utaustin

Publications of Results:
Responsible Party: University of Texas at Austin
ClinicalTrials.gov Identifier: NCT02361177     History of Changes
Other Study ID Numbers: 2013-11-0033
First Posted: February 11, 2015    Key Record Dates
Last Update Posted: June 13, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Antisocial Personality Disorder
Personality Disorders
Mental Disorders
Oxytocin
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs